Effect of spinal nalbuphine improves postoperative analgesia in patients after total knee Arthroplasty

a prospective, randomized controlled trial involving patients undergoing TKA who received adductor canal block and spinal anesthesia. The study included three groups, each with 14 patients: Group A (control), Group B (additional intrathecal nalbuphine 0.8 mg), and Group C (additional intrathecal nalbuphine 1.2 mg).

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

TCTR

Registry ID

TCTR20241012005

Enrollment

Registered

2024-10-12

Start date

2024-01-05

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute postoperative pain management Total knee replacement, nalbuphine, subarachnoid block,periarticular injection, and adductor canal block (ACB).

Interventions

Control group receiving spinal anesthesia with 0.2 mL normal saline combined with periarticular injection and ACB.,Nalbuphine 0.8 mg combined with spinal anesthesia, periarticular injection, and adduc

No Intervention No treatment,Experimental Drug,Experimental Drug

Control group ,Nalbuphine 0.8 mg ,Nalbuphine 1.2 mg

Eligibility

Sex/Gender

All

Age

40 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Patients undergoing unilateral knee replacement surgery performed by two surgeons. 2. Patients under spinal anesthesia (subarachnoid block) combined with periarticular injection and adductor canal block (ACB). 3. Age between 40 and 85 years. 4. ASA (American Society of Anesthesiologists) physical status classification of 1-3.

Exclusion criteria

Exclusion criteria: 1. Patients who refuse to participate in the study. 2. Patients who are unable to assess and report pain scores (cognitive impairment) or have psychiatric disorders. 3. Patients with anatomical abnormalities of the spine. 4. Patients with neuropathy or neurological deficits in one or both legs. 5. Patients with a GFR (glomerular filtration rate) < 50 mL/min. 6. Patients allergic to local anesthetics. 7. Patients allergic to the drugs used in the study (nalbuphine). 8. Patients with coagulation disorders, such as a platelet count of less than 80,000/uL or INR above 1.5, or those who have not appropriately discontinued anticoagulant or antiplatelet medications. 9. Patients with chronic pain requiring oral morphine above 20 mg per day. 10.Patients receiving other analgesics outside of the study protocol.

Design outcomes

Primary

Measure	Time frame
pain score 6, 12, 24, and 48 hours postoperatively numeric rating scale (NRS)	—

Secondary

Measure	Time frame
opioid 6, 12, 24, and 48 hours postoperatively the amount of opioid	—

Countries

Thailand

Contacts

Public Contactinthiporn kositanurit

naresuan university

inthipornk@nu.ac.th66867752512

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026